These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3764 related articles for article (PubMed ID: 3798106)

  • 1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
    Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
    Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
    Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
    J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of HER-2/neu amplification with breast cancer recurrence.
    Carr JA; Havstad S; Zarbo RJ; Divine G; Mackowiak P; Velanovich V
    Arch Surg; 2000 Dec; 135(12):1469-74. PubMed ID: 11115354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
    Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
    Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.
    Brouillet JP; Theillet C; Maudelonde T; Defrenne A; Simony-Lafontaine J; Sertour J; Pujol H; Jeanteur P; Rochefort H
    Eur J Cancer; 1990 Apr; 26(4):437-41. PubMed ID: 2141510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
    Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
    Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
    Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
    Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
    Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
    J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
    Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
    Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu oncogene protein and prognosis in breast cancer.
    Tandon AK; Clark GM; Chamness GC; Ullrich A; McGuire WL
    J Clin Oncol; 1989 Aug; 7(8):1120-8. PubMed ID: 2569032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
    Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.
    Schlotter CM; Vogt U; Bosse U; Mersch B; Wassmann K
    Breast Cancer Res; 2003; 5(2):R30-6. PubMed ID: 12631396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
    Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
    Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up study of HER-2/neu amplification in primary breast cancer.
    Clark GM; McGuire WL
    Cancer Res; 1991 Feb; 51(3):944-8. PubMed ID: 1988136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer.
    Machotka SV; Garrett CT; Schwartz AM; Callahan R
    Clin Chim Acta; 1989 Oct; 184(3):207-17. PubMed ID: 2611995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 189.